Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug
Maze Therapeutics stock was little changed in Thursday’s premarket trade as investors shrugged off a sparse update from the company. Focus is already shifting to June, when investor events could provide more detail on Maze’s main kidney-disease program. The stock fell about 1.2% to $26.05 in recent trade, leaving the South San Francisco biotech's market value near $1.4 billion. Biotech shares elsewhere traded higher. The SPDR S&P Biotech ETF was up 0.8%. The iShares Nasdaq Biotechnology ETF added 0.3%.